AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05398809
Drug: Ruxolitinib
RxNorm normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ruxolitinib (Jakafi) is approved by the FDA for the treatment of intermediate or high-risk myelofibrosis in adults, polycythemia vera in adults who have had an inadequate response to or are intolerant of hydroxyurea, and acute and chronic graft-versus-host disease in adult and pediatric patients (aged =12 years).
Trial: NCT05754333
Drug: pudexacianinium chloride
RxNorm normalized name: CHLORIDE
DrugBank: Pudexacianinium (DB19161)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous
Trial: NCT05104476
Drug: Lu AF82422
RxNorm normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for infusion
Trial: NCT04584307
Drug: Elotuzumab
RxNorm normalized name: elotuzumab
DrugBank: Elotuzumab (DB06317)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Elotuzumab 10-20mg/kg
Trial: NCT04584307
Drug: Pomalidomide
RxNorm normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pomalidomide 2mg
Trial: NCT04698330
Drug: Berberine
RxNorm normalized name: berberine
DrugBank: Berberine (DB04115)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6g (6 pills) of Berberine tablets administered twice a day orally before meal for 3 months
Trial: NCT04698330
Drug: Inulin
RxNorm normalized name: Inulin
DrugBank: Inulin (DB00638)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 0.6g (6 pills) of Inulin tablets administered twice a day orally before meal for 3 months
Trial: NCT04698330
Drug: Berberine placebo tablets
RxNorm normalized name: berberine
DrugBank: Berberine (DB04115)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6g (6 pills) of Berberine placebo tablets administered twice a day orally before meal for 3 months
Trial: NCT04698330
Drug: Inulin placebo tablets
RxNorm normalized name: placebo Oral Tablet
DrugBank: Inulin (DB00638)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 0.6g (6 pills) of Inulin placebo tablets administered twice a day orally before meal for 3 months
Trial: NCT05246111
Drug: [14C]Berzosertib
DrugBank: Berzosertib (DB11794)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received single intravenous infusion of \[14C\]Berzosertib at a dose of 210 milligrams per square meter (mg/m\^2) on Day 1 in Period 1 and stay in clinical research unit (CRU) is required until the discharge criteria are met with a maximum confinement period of 15 days.
Trial: NCT04863430
Drug: Apatinib
RxNorm normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500mg oral qd
Trial: NCT04863430
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 130mg/m\^2 administered as IV infusion on Days 1 of each 21-day cycle
Trial: NCT05246111
Drug: Berzosertib
RxNorm normalized name: Berzosertib
DrugBank: Berzosertib (DB11794)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received single intravenous infusion of Berzosertib at a dose of 210 mg/m\^2 on Day 2 and Day 5 in period 2 until disease progression or other criteria for study intervention discontinuation were met.
Trial: NCT05246111
Drug: Topotecan
RxNorm normalized name: Topotecan
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants received topotecan at a dose of 1.25 mg/m\^2 intravenously on Days 1 through 5 of each 21-day cycle in period 2 until disease progression or other criteria for study intervention discontinuation were met.
Trial: NCT05317000
Drug: Combination 5-azacytidine and nivolumab
DrugBank: Cytidine (DB02097)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The primary objective of the study is to determine whether exposure to the demethylating agent 5-azacytidine will sensitize HPV-associated oropharynx cancer to nivolumab by induction of interferon response, neoantigen expression, and augmentation of lymphocyte infiltration of the tumor microenvironment.
Trial: NCT05317000
Drug: 5-azacytidine
RxNorm normalized name: 5-azacytidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Chemotherapy is the use of drugs to destroy cancer cells. It usually works by keeping the cancer cells from growing, dividing, and making more cells. Because cancer cells usually grow and divide faster than normal cells, chemotherapy has more of an effect on cancer cells. 5-azacytidine works by slowing down the growth of cancer cells. 5-azacytidine has been demonstrated to improve the cell's ability to make some proteins which signal to the immune system.
Trial: NCT04863430
Drug: S1
RxNorm normalized name: LS11
DrugBank: LS11 (DB05918)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: According to body surface area,(\<1.5m\^2) 40mg or (≥1.5m\^2)50mg bid oral on Day 1-14 of each 21-day cycle
Trial: NCT03952299
Drug: Oxybutynin Transdermal Patch
RxNorm normalized name: oxybutynin Transdermal Product
DrugBank: Oxybutynin (DB01062)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal patch of oxybutynin will be used instead of oral oxybutynin.
Trial: NCT03952299
Drug: Oral Oxybutynin
DrugBank: Oxybutynin (DB01062)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of oxybutynin (5mg) every 8 hours in the hospital.
Trial: NCT05317000
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Immunotherapy is a type of treatment that uses your body's own immune system to help fight cancer. Specifically, Nivolumab belongs to a class of anti-cancer drugs known as immune checkpoint inhibitors. Cancer cells are able to turn off the immune system by increasing the production of a protein called PD-1. Nivolumab can block PD-1 and may be able to re-activate the immune response to kill head and neck cancer cells.
Trial: NCT05576597
Drug: Sodium Butyrate
RxNorm normalized name: Sodium butyrate
DrugBank: Butyric Acid (DB03568)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 capsules butyrate supplement once a day for 12 weeks
Trial: NCT00002167
Drug: Tin ethyl etiopurpurin
RxNorm normalized name: Tin ethyl etiopurpurin
DrugBank: Rostaporfin (DB06659)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05264714
Drug: Rimegepant
RxNorm normalized name: RIMEGEPANT
DrugBank: Rimegepant (DB12457)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150 mg oral disintegrating tablet every other day for one week
Trial: NCT05655806
Drug: Aminophylline bolus then infusion
RxNorm normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: half an hour before discontinuation of isoflurane
Trial: NCT05655806
Drug: aminophylline bolus
RxNorm normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: after discontinuation of isoflurane
Trial: NCT06209203
Drug: lowe-dose ZKY001 eye drops
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: eye drops
Trial: NCT06209203
Drug: Medium-dose ZKY001 eye drops
RxNorm normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eye drops
Trial: NCT06133517
Drug: Sacituzumab govitecan
RxNorm normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sacituzumab govitecan is administered at 10 mg/kg as an intravenous (IV) infusion on Days 1 and 8 of a 21-day cycle.
Trial: NCT06133517
Drug: Zimberelimab
RxNorm normalized name: Zimberelimab
DrugBank: Zimberelimab (DB17505)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZIM is administered at 360 mg every 3 weeks as an intravenous (IV) infusion on Day 1 of a 21-day cycle.
Trial: NCT06133517
Drug: Domvanalimab
RxNorm normalized name: Domvanalimab
DrugBank: Domvanalimab (DB18848)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DOM is administered at 1200 mg every 3 weeks as an intravenous (IV) infusion on Day 1 of a 21-day cycle.
Trial: NCT05776056
Drug: Methylphenidate
RxNorm normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate 10mg will be taken twice daily.
Trial: NCT06475742
Drug: Cenerimod
RxNorm normalized name: Cenerimod
DrugBank: Cenerimod (DB12705)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film-coated tablets at a dose of 4 mg.
Trial: NCT04936035
Drug: ALN-AGT01
RxNorm normalized name: ALN-AT3SC
DrugBank: Fitusiran (DB15002)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALN-AGT01 administered by SC injection
Trial: NCT06214793
Drug: Taletrectinib
RxNorm normalized name: taletrectinib
DrugBank: taletrectinib (DB18711)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taletrectinib (AB-106/DS-6051b) is a potent, highly selective, orally bioavailable ROS1 and TRK family inhibitor, which has activity against mutations conferring resistance to crizotinib including in vitro and in vivo against the acquired ROS1 G2032R solvent front mutation. Taletrectinib has been shown to have anti-tumor activity against recombinant ROS1, NTRK1, and NTRK3 in sub-nanomolar concentration in an ATP dependent manner, in addition to completely inhibiting ACK, ALK, DDR1 and LTK at micromolar concentrations. Anti-tumor activity of taletrectinib was observed in two ROS1 rearranged lung cancer cell lines, glioblastoma cell line, and in NTRK-rearranged colorectal cancer cell lines.
Trial: NCT06588413
Drug: Olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will be randomized to either olanzapine 2.5 mg or 5 mg
Trial: NCT06197776
Drug: cisplatin-based chemoradiotherapy combined with immunotherapy
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemotherapy:cisplatin-based chemotherapy~GP/TP/PF/TPF~Choice of chemotherapy regimen is decided by patient's doctor in charge.~Radiation: Intensity Modulated Radiation Therapy~All target volumes will be outlined slice by slice on the axial contrast-enhanced CT with MR fusion images in the treatment planning system. The target volumes are defined in accordance with the International Commission on Radiation Units and Measurements Reports 83. The prescribed dose is 70-72 Gy to PTVp (Planning target volume of the primary tumor), 64-70 Gy to PTVn (Planning target volume of the lymph node),60- 64Gy to PTV1 (High-risk planning target volume), and 54-58 Gy to PTV2 (Low-risk planning target volume) in 30-32 fractions. The details of dose limits for organs at risk are based on the study 0225 from The Radiation Therapy Oncology Group (RTOG 0225).~Immunotherapy:PD-1 blocking antibody
Trial: NCT04754425
Drug: Erdafitinib
RxNorm normalized name: erdafitinib
DrugBank: Erdafitinib (DB12147)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT04774068
Drug: Parsaclisib
RxNorm normalized name: Parsaclisib
DrugBank: Parsaclisib (DB14867)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT04774068
Drug: Romidepsin
RxNorm normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT05652322
Drug: Furosemide Pill 150% equivalent iv dose
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: change from intravenous to oral furosemide
Trial: NCT05652322
Drug: Furosemide Pill 200% equivalent iv dose
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: change from intravenous to oral furosemide
Trial: NCT05652322
Drug: Furosemide Injection
RxNorm normalized name: furosemide Injection
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: change from intravenous to oral furosemide
Trial: NCT06327646
Drug: Multiple Micronutrient Supplement Bottle
RxNorm normalized name: bottlebrush pollen extract
DrugBank: Callistemon citrinus pollen (DB10943)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMS in bottles along with related job aids, counselling during ANC, etc.
Trial: NCT06317350
Drug: GNS-212-ER
RxNorm normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects who are randomized into this group will take active control drug (PEG3350) from the evening before colonoscopy to the morning of colonoscopy.
Trial: NCT04617522
Drug: Sacituzumab Govitecan-hziy
RxNorm normalized name: sacituzumab govitecan-hziy
DrugBank: Sacituzumab govitecan (DB12893)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered intravenously
Trial: NCT05148702
Drug: Antibiotic - fixed-extended-duration
RxNorm normalized name: oxymetazoline hydrochloride Nasal Spray [Duration]
DrugBank: Oxymetazoline (DB00935)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clinician decided antibiotic for a fixed duration of 28 days.
Trial: NCT04551521
Drug: Vemurafenib
RxNorm normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 960 mg twice daily during run-in Phase, followed by 720 mg twice daily
Trial: NCT04551521
Drug: Cobimetinib
RxNorm normalized name: Cobimetinib
DrugBank: Cobimetinib (DB05239)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 60 mg once daily
Trial: NCT04551521
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 840 mg every 2 weeks
Trial: NCT04551521
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 8 mg per kilogram of body weight as a loading dose, followed by 6 mg per kilogram every 3 weeks
Trial: NCT04551521
Drug: Pertuzumab
RxNorm normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 840 mg as a loading dose, followed by 420 mg intravenously every 3 weeks
Trial: NCT04551521
Drug: Alectinib
RxNorm normalized name: Alectinib
DrugBank: Alectinib (DB11363)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 600 mg twice daily
Trial: NCT04551521
Drug: Ipatasertib
RxNorm normalized name: Ipatasertib
DrugBank: Ipatasertib (DB11743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg once daily
Trial: NCT04551521
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1200 mg every 3 weeks
Trial: NCT04551521
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1200 mg in the first cycle, followed by 840 mg every 3 weeks
Trial: NCT04551521
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1,200 mg every 3 weeks
Trial: NCT04551521
Drug: Inavolisib
RxNorm normalized name: Inavolisib
DrugBank: Inavolisib (DB15275)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9 mg once daily
Trial: NCT05473234
Drug: Amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Children enrolled in the trial and randomized to receive amoxicillin will receive a 5-day course of amoxicillin to be given in twice-daily doses of 15 mg/kg per the Nigeria guidelines for severe acute malnutrition. The first dose will be administered at the time of enrollment, and the remaining doses will be administered by the caregiver at home. Enrolled children will also receive RUTF.
Trial: NCT05890768
Drug: Lumateperone
RxNorm normalized name: Lumateperone
DrugBank: Lumateperone (DB06077)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FDA approved antipsychotic drug
Trial: NCT05527834
Drug: Ceftibuten
RxNorm normalized name: Ceftibuten
DrugBank: Ceftibuten (DB01415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single oral dose
Trial: NCT05890768
Drug: Risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: FDA approved antipsychotic drug
Trial: NCT06524687
Drug: Imvotamab
RxNorm normalized name: Imvotamab
DrugBank: Imvotamab (DB17331)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously
Trial: NCT04485039
Drug: Tecovirimat
RxNorm normalized name: Tecovirimat
DrugBank: Tecovirimat (DB12020)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: oral antiviral
Trial: NCT04485039
Drug: sevelamer carbonate oral tablet
RxNorm normalized name: sevelamer carbonate Oral Tablet
DrugBank: Sevelamer (DB00658)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: phosphate binder
Trial: NCT04485039
Drug: sucroferric oxyhydroxide chewable tablet
RxNorm normalized name: sucroferric oxyhydroxide Chewable Tablet
DrugBank: Ferric sulfate (DB11171)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: phosphate binder
Trial: NCT04485039
Drug: Lanthanum Carbonate Chewable Tablet
RxNorm normalized name: lanthanum carbonate Chewable Tablet
DrugBank: Lanthanum carbonate (DB06792)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: phosphate binder
Trial: NCT04918186
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1500mg IV, 60 min day 1 every 4 weeks
Trial: NCT04918186
Drug: ENB003
RxNorm normalized name: ENB003
DrugBank: ENB-003 (DB17340)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV
Trial: NCT04918186
Drug: Toripalimab
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV
Trial: NCT04785196
Drug: APG-115
RxNorm normalized name: APGA
DrugBank: Aminopterin (DB08878)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose escalation of APG-115 in combination with label dose of toripalimab, four dose levels of APG-115 will be tested: 50, 100, 150, and 200mg. APG-115 will be administrated orally every other day (QOD) for consecutive 2 weeks (ie. dosed at Day 1, 3, 5, 7, 9, 11, and 13), with one week dosing off as 3 weeks a cycle.
Trial: NCT04785196
Drug: Toripalimab
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toripalimab is administrated following CDE approved label dose, i.e.: 240 mg intravenous infusion at Day 1 of every 3 weeks as a cycle.
Trial: NCT06121011
Drug: Miglustat
RxNorm normalized name: Miglustat
DrugBank: Miglustat (DB00419)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants received ATB200 co-administered with AT2221 (Miglustat)
Trial: NCT05786443
Drug: Empagliflozin 10 MG
RxNorm normalized name: empagliflozin 10 MG
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sodium glucose cotransporter 2 inhibitor (SGLT2i) dosed once-daily over 12 weeks. Administered as oral tablet.
Trial: NCT04947059
Drug: Gemcitabine Hydrochloride combined with continuous saline irrigation
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Immediate single intravesical instillation with gemcitabine combined with continuous saline irrigation in bladder cancer patients who are treated with a transurethral resection of the tumor
Trial: NCT04947059
Drug: Epirubicin Hydrochloride combined with continuous saline irrigation
RxNorm normalized name: epirubicin hydrochloride Irrigation Solution
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immediate single intravesical instillation with epirubicin combined with continuous saline irrigation in bladder cancer patients who are treated with a transurethral resection of the tumor
Trial: NCT06134531
Drug: MR001
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dose Level 1: 0.5 mg/kg Intravenously (IV) Frequency: administered on Day 1 of each cycle (every 3 weeks), 1 cycle~Dose Level 2: 2 mg/kg Intravenously (IV) Frequency: administered on Day 1 of each cycle (every 3 weeks), 4 cycle~Dose Level 3: 6 mg/kg Intravenously (IV) Frequency: administered on Day 1 of each cycle (every 3 weeks), 4 cycle~Dose Level 4: 10 mg/kg Intravenously (IV) Frequency: administered on Day 1 of each cycle (every 3 weeks), 4 cycle~Dose Level 5: 15 mg/kg Intravenously (IV) Frequency: administered on Day 1 of each cycle (every 3 weeks), 4 cycle~Dose Level 6: 20 mg/kg Intravenously (IV) Frequency: administered on Day 1 of each cycle (every 3 weeks), 4 cycle
Trial: NCT05355701
Drug: PF-07799933
RxNorm normalized name: PF-07799933
DrugBank: PF-07799933 (DB17489)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT05355701
Drug: binimetinib
RxNorm normalized name: binimetinib
DrugBank: Binimetinib (DB11967)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablet
Trial: NCT05494866
Drug: Cobicistat Oral Tablet
RxNorm normalized name: cobicistat Oral Tablet
DrugBank: Cobicistat (DB09065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cobicistat Oral Tablet
Trial: NCT05494866
Drug: Gemcitabin
RxNorm normalized name: Gemcitabin
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabin
Trial: NCT05494866
Drug: Nab paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: nab-Paclitaxel
Trial: NCT05467891
Drug: Ribociclib
RxNorm normalized name: Ribociclib
DrugBank: Ribociclib (DB11730)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 400 mg orally once daily Days 1-21 (28 day Cycle)
Trial: NCT05467891
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 500 mg intramuscularly on Day 1 and 15 of Cycle 1 then Day 1 of Cycle 2+
Trial: NCT05467891
Drug: Anastrozole
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 mg orally once daily
Trial: NCT05467891
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2.5 mg orally once daily
Trial: NCT05467891
Drug: Exemestane
RxNorm normalized name: Exemestane
DrugBank: Exemestane (DB00990)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 mg orally once daily